Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Rituximab: an effective treatment for rheumatologic and digestive symptoms of celiac disease?

Palazzo C, Nicaise-Roland P, Palazzo E.

Joint Bone Spine. 2012 Jul;79(4):422-3. doi: 10.1016/j.jbspin.2012.01.011. Epub 2012 Mar 7. No abstract available.

PMID:
22401783
2.

First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.

Nikiphorou E, Hall FC.

Rheumatology (Oxford). 2014 Oct;53(10):1906-7. doi: 10.1093/rheumatology/keu161. Epub 2014 Apr 11. No abstract available.

PMID:
24729401
3.

Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).

Glace B, Gottenberg JE, Mariette X, Philippe R, Pereira B, Lequerré T, Berthelot JM, Dougados M, Toussirot E, Pham T, Allanore Y, Loeuille D, Euller-Ziegler L, Soubrier M.

Ann Rheum Dis. 2012 Aug;71(8):1429-31. doi: 10.1136/annrheumdis-2011-200915. Epub 2012 Apr 13. No abstract available.

PMID:
22504557
4.

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.

Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.

5.

Smoking, rheumatoid factor status and responses to rituximab.

Khan A, Scott DL, Batley M.

Ann Rheum Dis. 2012 Sep;71(9):1587-8. doi: 10.1136/annrheumdis-2012-201758. Epub 2012 Apr 24. No abstract available.

PMID:
22532635
6.

Rituximab therapy for AA-amyloidosis secondary to rheumatoid arthritis.

Narváez J, Hernández MV, Ruiz JM, Vaquero CG, Juanola X, Nollaa JM.

Joint Bone Spine. 2011 Jan;78(1):101-3. doi: 10.1016/j.jbspin.2010.09.020. Epub 2010 Nov 9. No abstract available.

PMID:
21067952
7.

Idiopathic orbital inflammation successfully treated using rituximab in a patient with rheumatoid arthritis.

Ibrahim I, Barton A, Ibrahim A, Ho P.

J Rheumatol. 2012 Jul;39(7):1485-6. doi: 10.3899/jrheum.111230. No abstract available. Erratum in: J Rheumatol. 2012 Sep;39(9):1908.

PMID:
22753803
8.

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators.

Ann Rheum Dis. 2011 Jan;70(1):39-46. doi: 10.1136/ard.2010.137703. Epub 2010 Oct 11.

PMID:
20937671
9.

[Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].

Samborski W, Buczek J, Bednarek A, Lewandowicz J, Kucharz E.

Pol Merkur Lekarski. 2010 Dec;29(174):365-8. Polish.

PMID:
21298986
10.

Autonomic imbalance in celiac children.

Barbato M, Curione M, Amato S, Carbone J, Briani C, Pannone V, Maiella G, Di Camillo C, Panetti D, Cucchiara S.

Minerva Pediatr. 2010 Aug;62(4):333-8.

PMID:
20940666
11.

Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19.

Bacconnier L, Combe B, Canaud B, Morel J.

Rheumatology (Oxford). 2010 Dec;49(12):2452-3. doi: 10.1093/rheumatology/keq186. Epub 2010 Jun 29. No abstract available.

PMID:
20591832
12.

Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

Belmonte Serrano MA, Pincus T.

Rheumatology (Oxford). 2010 Sep;49(9):1795-6; author reply 1796-7. doi: 10.1093/rheumatology/keq141. Epub 2010 May 19. No abstract available.

PMID:
20484342
13.

Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity.

Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP, Bijlsma JW, Lafeber FP, Redegeld FA, van Roon JA.

Ann Rheum Dis. 2010 Dec;69(12):2137-44. doi: 10.1136/ard.2009.126441. Epub 2010 Aug 2.

PMID:
20679475
14.

Rituximab treatment for persistent scleritis associated with rheumatoid arthritis.

Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T.

Ocul Immunol Inflamm. 2010 Jun;18(3):223-5. doi: 10.3109/09273941003739928.

PMID:
20482403
15.

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.

Bukhari M, Abernethy R, Deighton C, Ding T, Hyrich K, Lunt M, Luqmani R, Kiely P, Bosworth A, Ledingham J, Ostör A, Gadsby K, McKenna F, Finney D, Dixey J; BSR and BHPR Standards, Guidelines and Audit Working Group.

Rheumatology (Oxford). 2011 Dec;50(12):2311-3. doi: 10.1093/rheumatology/ker106a. Epub 2011 May 4. No abstract available.

PMID:
21546351
16.

The updated guidelines on the use of rituximab in rheumatoid arthritis.

Lopez-Olivo MA, Tayar JH, Suarez-Almazor ME.

Rheumatology (Oxford). 2011 Dec;50(12):2153-4. doi: 10.1093/rheumatology/ker149. Epub 2011 May 4. No abstract available.

PMID:
21546350
17.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
18.

Refractory anti-synthetase syndrome treated with rituximab.

Ball EM, Savage EM, Pendleton A.

Rheumatology (Oxford). 2010 May;49(5):1013. doi: 10.1093/rheumatology/kep438. Epub 2009 Dec 23. No abstract available.

PMID:
20032227
19.

Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis.

Dudler J, Finckh A, Kyburz D, Langenegger T, Möller B, Schmiedel U, Walker UA.

Swiss Med Wkly. 2010 Jul 16;140:w13073. doi: 10.4414/smw.2010.13073.

20.

Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

Arts EE, Jansen TL, Den Broeder A, Vonkeman HE, Dutmer E, Van de Laar MA, Van Riel PL, Fransen J.

Ann Rheum Dis. 2011 May;70(5):877-8. doi: 10.1136/ard.2010.136093. Epub 2010 Oct 18. No abstract available.

PMID:
20956405

Supplemental Content

Support Center